Epedigree in the Pharmaceutical Supply Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Epedigree in the Pharmaceutical Supply Chain
The author examines the current regulatory and legislative framework for ePedigree for finished drug products as well as proposals to require electronic statements for pharmaceutical ingredients.


Pharmaceutical Technology


Tools for integration

Connectivity and interoperability between suppliers and their customer are two issues to consider when trying to create an custody-tracking solution. "Companies face the need to share data and increase visibility within the supply chain but are reluctant to increase their investment in technology," says Pease. "Making an additional investment in eCommerce infrastructure often means increased costs and resource drain as a result of building an in-house solution or burdening existing systems for connecting a company with its trading partners."

Enterprise-resource planning (ERP), EDI, enterprise application integration (EAI), and other business-to-business applications may be used to link systems together. As the complexity of the supply chain increases, however, a supplier has to consider how these systems can be linked. "Companies may find themselves having to decide among undesirable alternatives," says Pease. These alternatives may include the following:

  • Change business relationships, discontinue and/or restrict distribution, or assume additional risks
  • Continue existing supply-chain relationships while adding manual processes that increase costs and delay delivery
  • Implement complex, expensive hardware and software solutions that require dedicated information technology resources that may not scale.

"No company wants to disrupt business processes, introduce delivery delays, increase operating expenses, and potentially reduce revenue," says Pease. "Organizations' legacy systems such as EDI and flat-file transfer are no longer enough. Low-level connections that only transfer batch files between applications and trading partners are giving way to smart networks that incorporate diverse integration functionality that provide integration with business processes and ERP systems," he says.


Figure 1 (COURTESY OF HUBSPAN.)
Instead, Pease points to the value of software-as-a-service (SaS) delivery model. SaS is a delivery model for business-processes integration among trading partners. Figure 1 outlines a custody-tracking solution. The hosted, managed service allows suppliers to send and receive documents electronically without having to make an additional investment in e-commerce infrastructure or upgrading existing systems. The product custody data is transmitted straight to their respective backend systems. The solution can be delivered as a portal or as a fully integrated service to translate and validate data to make it readily usable by in-house systems. To maintain data integrity throughout the supply chain, the offering should provide a central repository to ensure the safety of data so that the products' custody information can be tracked across the supply chain, without impacting trading partners' IT infrastructures and business processes, explains Pease.

The SaS model is an alternative to deploying cross-enterprise integration software or developing an in-house solution. Rapid deployment, accessibility, flexibility, and scalability are advantages of such an approach, says Pease. A typical deployment may be operational in several weeks. All participants should be able to communicate via a single connection and may use a platform using business-to-business applications, EAI, ERP systems or a secure portal for tracking transactions. The solution can also add process-automation features such as generating e-mail notifications in the case of incomplete or incorrect transactions. Transactions can either be resubmitted or corrected manually via the secure portal. The system also creates an audit trail and a searchable archive of critical data.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here